16 related articles for article (PubMed ID: 11561769)
1. Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study.
Mozaffari F; Lindemalm C; Choudhury A; Granstam-Björneklett H; Lekander M; Nilsson B; Ojutkangas ML; Osterborg A; Bergkvist L; Mellstedt H
Cancer Immunol Immunother; 2009 Jan; 58(1):111-20. PubMed ID: 18488220
[TBL] [Abstract][Full Text] [Related]
2. Comparing serum levels of cardiac biomarkers in cancer patients receiving chemotherapy and subjects with chronic periodontitis.
Loo WY; Yue Y; Fan CB; Bai LJ; Dou YD; Wang M; Liang H; Cheung MN; Chow LW; Li JL; Tian Y; Qing L
J Transl Med; 2012 Sep; 10 Suppl 1(Suppl 1):S5. PubMed ID: 23046680
[TBL] [Abstract][Full Text] [Related]
3. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.
Erselcan T; Kairemo KJ; Wiklund TA; Hernberg M; Blomqvist CP; Tenhunen M; Bergh J; Joensuu H
Br J Cancer; 2000 Feb; 82(4):777-81. PubMed ID: 10732745
[TBL] [Abstract][Full Text] [Related]
4. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study.
Hernberg M; Virkkunen P; Maasilta P; Keyriläinen J; Blomqvist C; Bergh J; Wiklund T
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):128-36. PubMed ID: 11777630
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
[TBL] [Abstract][Full Text] [Related]
7. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
8. Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients.
Hall KS; Wiklund T; Erikstein B; Holte H; Kvalheim G; Sommer HH; Andersen A; Skovlund E; Bergh J; Hall C
Breast Cancer Res Treat; 2001 Jun; 67(3):235-44. PubMed ID: 11561769
[TBL] [Abstract][Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
